What is Californian dysplasia, also known as Fibrodysplasia (Fibrous Dysplasia) Ossificans Progressiva (FOP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Fibrodysplasia Ossificans Progressiva (FOP), also known as Fibrous Dysplasia, is a severely disabling heritable disorder of connective tissue characterized by congenital malformations of the great toes and progressive heterotopic ossification (HO) that forms qualitatively normal bone in characteristic extra-skeletal sites. This condition is estimated to have a worldwide prevalence of 1/1 300 000 to 1/2 000 000 1. The diagnosis of FOP can be made by clinical evaluation, with confirmatory genetic testing available, and is caused by a recurrent activating mutation in the gene encoding Activin A receptor type I/Activin-like kinase 2 (ACVR1/ALK2) 1.

Key Characteristics of FOP

  • Congenital malformations of the great toes
  • Progressive HO that forms qualitatively normal bone in characteristic extra-skeletal sites
  • Sporadic episodes of painful soft tissue swellings (‘flare-ups’) that transform skeletal muscles, tendons, ligaments, fascia, and aponeuroses into heterotopic bone
  • No ethnic, racial, gender, or geographic predilections

Management and Treatment

  • At present, there are no definitive treatments for FOP, but a brief, 4-day course of high-dose corticosteroids combined with nonsteroidal anti-inflammatory drugs (NSAIDs) may help to reduce the intense inflammation and tissue edema seen in the early stages of the disease 1
  • Preventative management is based on prophylactic measures against falls, respiratory decline, and viral infections
  • The median estimated lifespan is 56 years, with most patients being wheelchair-bound by the end of the second decade of life and commonly dying of complications of thoracic insufficiency syndrome 1

Important Considerations

  • Delayed diagnosis can still occur despite the hallmark changes in great toes
  • Differential diagnoses include progressive osseous heteroplasia (POH), osteosarcoma, lymphoedema, soft tissue sarcoma, desmoid tumours, aggressive juvenile fibromatosis, calcinosis of skin and muscles, infection, and non-hereditary (acquired) heterotopic ossification 1

From the Research

Definition and Characteristics of Fibrous Dysplasia

  • Fibrous dysplasia (FD) is a benign skeletal disorder that can affect one or multiple bones, often involving long bones, ribs, and craniofacial bones 2, 3, 4, 5.
  • It is characterized by bone deformities, pain, and iterative fractures, and can also present with endocrine dysfunction and cutaneous café-au-lait spots 3.
  • The disease can be monostotic (affecting one bone) or polyostotic (affecting multiple bones) 4, 5.

Etiology and Pathophysiology

  • Fibrous dysplasia is caused by a somatic activating mutation of the Gs alpha subunit of protein G, resulting in an increased cAMP concentration and abnormalities of osteoblast differentiation 3.
  • This leads to the production of abnormal bone and an increase in interleukin-6-induced osteoclastic bone resorption 3.

Diagnosis and Treatment

  • Diagnosis relies on X-ray examination and pathology 3.
  • Treatment options include bisphosphonate therapy, which can help improve function, decrease pain, and lower fracture risk in selected patients 2, 3, 5, 6.
  • Surgery is indicated for confirmatory biopsy, correction of deformity, prevention of pathologic fracture, and/or eradication of symptomatic lesions 5.
  • Calcium, vitamin D, and phosphorus supplements may be useful in patients with deficiency 6.

Prognosis and Complications

  • The prognosis is generally good, although poor outcomes are more frequent in younger patients and in those with polyostotic forms of the disease 4.
  • The risk of malignant transformation is low 4.
  • Complications can include nerve compression and malignant transformation, although these are uncommon 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fibrous dysplasia of bone.

Bailliere's best practice & research. Clinical rheumatology, 2000

Research

Fibrous dysplasia.

The Journal of the American Academy of Orthopaedic Surgeons, 2004

Research

Fibrous dysplasia. Pathophysiology, evaluation, and treatment.

The Journal of bone and joint surgery. American volume, 2005

Research

Medical therapy in adults with fibrous dysplasia of bone.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.